334769-80-1

Basic information

• Product Name: (2S,5S)-N-Boc-5-methylpyrrolidine-2-carboxylic acid
• Synonyms: (2s,5s)-n-boc-5-methylpyrrolidine-2-carboxylic acid;(2S,5S)- 5-Methyl-1,2-pyrrolidinedicarboxylic acid 1-(1,1-dimethylethyl) ester;(2S,5S)-1-(tert-Butoxycarbonyl)-5-methylpyrrolidine-2-carboxylic acid;(2S,5S)-N-Boc-5-Methylpyrrolidine-2-carboxylic aci;GS-5817 interMediate;2. (2S,5S)-1-(tert-butoxycarbonyl)-5-methylpyrrolidine-2-carboxylic acid;(2S,5S)-N-Boc-5-methylpyrrolidine-2-carboxylic acid(2S,5S)-N-Boc-5-methylpyrrolidine-2-carboxylic acid;(2S,5S)-5-methyl-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid
• CAS NO: 334769-80-1
• Molecular Formula: C₁₁H₁₉NO₄
• Molecular Weight: 229.27
• Mol File: 334769-80-1.mol
• Article Data: 20

Chemical Properties

• Boiling Point: 343.2 °C at 760 mmHg
• Flash Point: 161.4 °C
• Appearance: /
• Density: 1.150
• Refractive Index: 1.49
• Storage Temp.: 2-8°C
• PKA: 4.02±0.40(Predicted)
• CAS DataBase Reference: (2S,5S)-N-Boc-5-methylpyrrolidine-2-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: (2S,5S)-N-Boc-5-methylpyrrolidine-2-carboxylic acid(334769-80-1)
• EPA Substance Registry System: (2S,5S)-N-Boc-5-methylpyrrolidine-2-carboxylic acid(334769-80-1)

Safety Data

• Hazardous Substances Data: 334769-80-1(Hazardous Substances Data)

Usage

General Description

The chemical compound "(2S,5S)-N-Boc-5-methylpyrrolidine-2-carboxylic acid" is a derivative of pyrrolidine, which is a five-membered heterocyclic compound. It has a Boc (tert-butoxycarbonyl) protecting group on the nitrogen atom and a carboxylic acid group on the second carbon of the pyrrolidine ring. The stereochemistry of the compound is designated as (2S,5S), indicating the configuration of the chiral centers in the molecule. (2S,5S)-N-Boc-5-methylpyrrolidine-2-carboxylic acid is commonly used in organic synthesis as a chiral building block and as a precursor for the synthesis of pharmaceuticals and other biologically active molecules.

InChI:InChI=1/C11H19NO4/c1-7-5-6-8(9(13)14)12(7)10(15)16-11(2,3)4/h7-8H,5-6H2,1-4H3,(H,13,14)/t7-,8-/m0/s1

Upstream product

• 4931-66-2 methyl (S)-pyroglutamate 
• 913251-58-8 (S)-2-(tert-butoxycarbonylamino)-5-oxohexanoic acid ethyl ester 
• 896733-29-2 (S)-5-methyl-3,4-dihydro-2H-pyrrole-2-carboxylic acid ethyl ester 
• 676560-83-1 (2S,5S)-5-methyl-pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 2-ethyl ester 
• 24424-99-5 di-tert-butyl dicarbonate 
• 38533-38-9 (5S,2S)-(-)-5-methylproline 
• 98-79-3 L-Pyroglutamic acid 
• 94885-52-6 benzyl (L)-pyroglutamate 
• 54824-06-5 C₁₃H₁₇NO₂ 
• 113400-46-7 benzyl (2S)-2-[(tert-butoxycarbonyl)amino]-5-oxohexanoate 
• 113400-36-5 benzyl (2S)-N-tert-butoxycarbonyl-5-oxoprolinate 
• 915157-02-7 (2S,5S)-methyl 5-methylpyrrolidine-2-carboxylate 
• 108963-96-8 (S)-1-tert-butoxycarbonyl-5-methoxycarbonyl-pyrrolidin-2-one 
• 7149-65-7 ethyl (S)-pyroglutamate 

Downstream Products

• 1250939-12-8 (2S,5S)-5-methyl-pyrrolidine-1,2-dicarboxylic acid 2-[2-(4-bromo-phenyl)-2-oxo-ethyl]ester 1-tert-butyl ester 
• 1378390-49-8 C₂₁H₂₇BrN₄O₃ 
• 1433280-50-2 methyl ((S)-3-methyl-1-((2S,5S)-2-methyl-5-(4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1H-imidazol-2-yl)pyrrolidin-1-yl)-1-oxobutan-2-yl)carbamate 
• 1033709-37-3 (5S)-1-{[(5R,6S)-5,6-bis(4-chlorophenyl)-3-isopropyl-6-methyl-5,6-dihydroimidazo[2,1-b][1,3]thiazol-2-yl]carbonyl}-N,N,5-trimethyl-L-prolinamide 
• 38533-38-9 (5S,2S)-(-)-5-methylproline 
• 1377049-84-7 methyl {(2S)-1-[(2S,5S)-2-(9-{2-[(2S,4S)-1-{(2R)-2-[(methoxycarbonyl)amino]-2-phenylacetyl}-4-(methoxymethyl)pyrrolidin-2-yl]-1H-imidazol-5-yl}-1,11-dihydroisochromeno[4′,3′:6,7]naphtho[1,2-d]imidazol-2-yl)-5-methylpyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl}carbamate 
• 1844064-96-5 (2S,4S)-2-[5-(2-{(2S,4S)-1-{N-(methoxycarbonyl)-L-valyl}-5-methylpyrrolidin-2-yl}-1,11-dihydroisochromene[4',3':6,7]naphtho[1,2-d]imidazol-9-yl)-1H-imidazol-2-yl]-4-(methoxymethyl)pyrrolidine 
• 1378391-45-7 tert-butyl (2S,4S)-2-[5-(2-{(2S,5S)-1-[N-(methoxycarbonyl)-L-valyl]-5-methylpyrrolidin-2-yl}-1,11-dihydroisochromeno[4′,3′:6,7]naphtho[1,2-d]imidazol-9-yl)-1H-imidazol-2-yl]-4-(methoxymethyl)pyrrolidine-1-carboxylate 

Relevant articles and documents

Compound used for inhibiting hepatitis C virus, and pharmaceutical applications thereof

The invention relates to a compound which is represented by formula I, is used for inhibiting hepatitis C virus, and possesses excellent bioavailability, and a nontoxic pharmaceutically acceptable salt thereof. The compound possesses extremely high inhibition effect on HCV of all genotypes. In the formula I, R is used for representing hydrogen atom, glycyl, L-alanyl, L-leucyl, L-valyl, or L-isoleucyl.

BRIDGED RING COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF

Provided herein is a bridged bring compound of formula (I) or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, which can be used for treating treat hepatitis C virus (HCV) infection or hepatitis C disease. Furthermore provided herein are pharmaceutical compositions containing the compounds and the method of using the compounds or pharmaceutical compositions thereof in the treatment of HCV infection or hepatitis C.

BRIDGED RING COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF

Provided herein is a bridged bring compound of formula (I) or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, which can be used for treating treat hepatitis C virus (HCV) infection or hepatitis C disease. Furthermore provided herein are pharmaceutical compositions containing the compounds and the method of using the compounds or harmaceutical com ositions thereof in the treatment of HCV infection or he atitis C.